Compare J B Hunt Transport Services Inc (JBHT) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J B Hunt Transport Services Inc vs Novo Nordisk A/S — how do they compare? J B Hunt Transport Services Inc trades at $229.26 (market cap $21.45B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 7.7× J B Hunt Transport Services Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold J B Hunt Transport Services Inc for 46 Days and Novo Nordisk A/S for 116 Days on average.
| JBHT | NVO | |
|---|---|---|
Market Cap | $21.45B | $165.31B |
Volume | 1,028,680 | 11,432,838 |
Sector | Industrials | Health |
52-Week High | $298.41 | $63.98 |
52-Week Low | $137.09 | $35.29 |
Typical Hold Time | 46 Days | 116 Days |
Enterprise Value | $22.59B | $179.56B |
Dividend Yield | 0.79% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBHT trades at $229.26, up 2.97% today, amid a bearish technical signal but strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue has stabilized around $12B, while profitability metrics like ROE (18.45%) and net margin (5.31%) remain solid. However, rising costs and ongoing securities litigation investigations present headwinds.
The outlook is mixed: Wall Street's consensus price target of $289.40 implies significant upside, but near-term pressure from fuel costs and legal overhangs may limit gains. Investors should weigh strong fundamentals against operational risks and market sentiment shifts ahead of Q3 earnings.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
